Earnings History Data for Cidara Therapeutics, Inc. (CDTX) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Cidara Therapeutics, Inc.
Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13-08-2024 | AH | CDTX | Cidara Therapeutics | 83.00 | -2.05 | -3.94 | 0.00 | Cidara Therapeutics GAAP EPS of -$20.65, revenue of $0.3M [8/13/2024 5:36 PM] |
12.78 | 0.63 (5.19%) |
12.55 | 0.40 (3.29%) |
10.00 - 24.40 | 41,156 | 10,000 | 1,230 | ||
| 15-05-2024 | AH | CDTX | Cidara Therapeutics | 58.00 | -2.28 | -1.50 | 0.00 | Cidara Therapeutics GAAP EPS of -$2.28 beats by $0.11, revenue of $8.46M misses by $0.57M [5/15/2024 5:08 PM] |
12.01 | -0.70 (-5.51%) |
12.07 | -0.64 (-5.04%) |
10.00 - 29.60 | 44,762 | 40,000 | 3,479 | ||
| 22-04-2024 | AH | CDTX | Cidara Therapeutics | 65.00 | -0.04 | -0.08 | 0.00 | Cidara Therapeutics GAAP EPS of -$0.04 beats by $0.06, revenue of $17.6M beats by $6.06M [4/22/2024 5:19 PM] |
0.5151 | 0.0 (0.23%) |
0.55 | 0.03 (6.60%) |
0.50 - 1.48 | 1,742,379 | 1,020,000 | 60,792 | ||
| 03-08-2023 | AH | CDTX | Cidara Therapeutics | 94.00 | -0.14 | -0.08 | 0.00 | Cidara Therapeutics GAAP EPS of -$0.14 misses by $0.01, revenue of $7.61M misses by $3.94M [8/3/2023 5:37 PM] |
0.9620 | -0.06 (-5.69%) |
1.00 | -0.02 (-1.96%) |
0.46 - 2.10 | 499,700 | 750,000 | 2,868 | ||
| 23-03-2023 | PM | CDTX | Cidara Therapeutics | 142.00 | -0.19 | -0.01 | 0.00 | Cidara Therapeutics GAAP EPS of -$0.19 misses by $0.04, revenue of $10.22M misses by $0.35M [3/23/2023 7:53 AM] |
1.44 | -0.46 (-24.47%) |
1.69 | -0.21 (-11.05%) |
0.40 - 2.10 | 11,465,800 | 5,400,000 | 1,212,380 | ||
|
||||||||||||||||||
| 03-11-2022 | AH | CDTX | Cidara Therapeutics | 41.00 | 0.17 | 0.30 | 0.00 | Cidara Therapeutics GAAP EPS of $0.17 beats by $0.10, revenue of $40.74M beats by $18.06M [11/3/2022 5:51 PM] |
0.5620 | -0.01 (-1.92%) |
0.58 | 0.01 (1.22%) |
0.40 - 1.76 | 195,098 | 220,000 | 7,276 | ||
| 09-08-2022 | AH | CDTX | Cidara Therapeutics | 48.00 | -0.19 | -0.28 | 0.00 | Cidara Therapeutics GAAP EPS of -$0.19 beats by $0.09, revenue of $6.22M beats by $0.01M [8/9/2022 5:25 PM] |
0.6525 | 0.03 (4.38%) |
0.65 | 0.02 (3.95%) |
0.40 - 2.39 | 439,944 | 1,490,000 | 2,143 | ||
|
||||||||||||||||||
| 11-05-2022 | AH | 5:40 PM ET (May 11) |
CDTX | Cidara Therapeutics | 50.00 | -0.27 | -0.26 | 0.00 | Cidara Therapeutics GAAP EPS of -$0.27 beats by $0.01, revenue of $7.11M beats by $2.4M [5/11/2022 4:56 PM] |
0.4601 | -0.13 (-22.65%) |
0.55 | -0.04 (-7.43%) |
0.41 - 2.39 | 1,135,300 | 190,000 | 5,036 | |
|
||||||||||||||||||
| 07-03-2022 | AH | CDTX | Cidara Therapeutics | 47.00 | -0.26 | -0.33 | 0.00 | Cidara Therapeutics GAAP EPS of -$0.26, revenue of $7.2M [3/7/2022 6:07 PM] |
0.7140 | 0.05 (7.00%) |
0.0 | 0.0 (0.00%) |
0.63 - 3.08 | 225,799 | 200,000 | 0 | ||
| 10-11-2021 | AH | CDTX | Cidara Therapeutics | 78.00 | -0.37 | -0.37 | 0.00 | Cidara Therapeutics EPS misses by $0.02, beats on revenue [11/10/2021 4:42 PM] |
1.52 | -0.01 (-0.65%) |
1.55 | 0.02 (1.31%) |
1.46 - 3.15 | 415,161 | 470,000 | 1,130 | ||
| 13-05-2021 | AH | 4:45 PM ET (May 13) |
CDTX | Cidara Therapeutics, Inc. | 97.06 | -0.39 | -0.17 | -0.46 | Cidara Therapeutics EPS misses by $0.05, misses on revenue [5/13/2021 5:17 PM] |
2.00 | -0.02 (-0.99%) |
2.01 | -0.01 (-0.50%) |
1.76 - 4.45 | 266,999 | 480,000 | 9,286 | |
| 05-11-2020 | AH | 4:50 PM ET (Nov 5) |
CDTX | Cidara Therapeutics, Inc. | 104.82 | -0.41 | -0.48 | 0.08 | Cidara Therapeutics EPS misses by $0.01, misses on revenue [11/5/2020 5:35 PM] |
2.34 | -0.20 (-7.87%) |
2.50 | 0.02 (0.81%) |
1.30 - 4.45 | 287,372 | 212,399 | 230 | |
|
|
||||||||||||||||||
| 13-08-2020 | AH | CDTX | Cidara Therapeutics, Inc. | 165.70 | -0.45 | -0.23 | -0.49 | Cidara Therapeutics EPS misses by $0.14, misses on revenue [8/13/2020 4:59 PM] |
3.78 | 0.0 (0.00%) |
0.0 | 0.0 (0.00%) |
1.22 - 4.45 | 104,321 | 203,500 | 0 | ||
|
|
||||||||||||||||||
| 13-05-2020 | AH | After the close (May 13) |
CDTX | Cidara Therapeutics, Inc. | 132.39 | -0.46 | -0.34 | -0.60 | Cidara Therapeutics EPS misses by $0.12, beats on revenue [5/13/2020 4:58 PM] |
2.99 | 0.07 (2.40%) |
2.95 | 0.03 (1.03%) |
1.22 - 4.44 | 146,384 | 293,949 | 320 | |
|
|
||||||||||||||||||